We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay for Biomarker Predicts Risk of Heart Failure

By LabMedica International staff writers
Posted on 26 Jan 2011
An enzyme-linked immunosorbent assay (ELISA) that measures galectin-3 in human plasma has been used to calculate the risk of heart failure (HF).

This ELISA assay quantitatively measures the concentration of human galectin-3 levels in EDTA plasma. This assay has high sensitivity with a lower limit of detection of 1.13 ng/mL) and exhibits no cross-reactivity with collagens or other members of the galectin family.

In a study carried out at the University Medical Center Groningen, (UMCG; Groningen, The Netherlands), blood samples were available from 592 heart failure patients during their index admission. Samples were also collected just before discharge when patients were stabilized and there was a mean follow-up of 18 months. Galectin-3 was measured by the ELISA method developed by BG Medicine (Waltham, MA, USA). Levels of cytokines vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), C-reactive protein (CRP), and transforming growth factor-β 1 (TGF-β 1) were measured in the same plasma samples using Search-Light Proteome Arrays (Aushon BioSystems, Billerica, MA, USA).

The investigators reported that the inflammatory markers were positively correlated to galectin-3 levels and the study confirmed that galectin-3 is a strong and independent predictor of adverse outcomes. The prognostic value of the galectin-3 biomarker remained even after adjustment for established risk factors for poor outcomes in HF, including age, sex, brain natriuretic peptide, renal function, and diabetes mellitus. The predictive power of plasma galectin-3 appears to be predominantly strong in heart failure patients with preserved left ventricular ejection fraction, which nowadays comprise about half of all HF patients. Serial measurements of galectin-3 do not appear to add to the prognostic power of single measurements. The details of the study were published in January 2011, in the journal Annals of Medicine.

Related Links:
University Medical Center Groningen
BG Medicine
Aushon BioSystems



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Latest Clinical Chem. News

Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring

Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples

AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood



Sekisui Diagnostics UK Ltd.